Product Details
| Product Name:
CU-T12-9 |
CAS No.:
1821387-73-8 |
| Purity:
99.93% |
Supply Ability:
10g |
| Release date:
2024/11/18 |
Product Introduction
Bioactivity
| Name | CU-T12-9 |
| Description | CU-T12-9 is a potent TLR1/2 agonist(EC50 of 52.9 nM in HEK-Blue hTLR2 SEAP assay). It acts by activating the NFkB pathway, upregulating proinflammatory cytokines, and enhancing TLR1 and TLR2 dimerization.CU-T12-9 activates both the innate and the adaptive immune systems. CU-T12-9 selectively activates the TLR1/2 heterodimer, not TLR2/6. CU-T12-9 signals through NF-κB and invokes an elevation of the downstream effectors TNF-α, IL-10, and iNOS. |
| In vitro | CU-T12-9 directly targets TLR1/2 to initiate downstream signaling. It specifically induces TLR1/2 activation, which can be blocked by either the anti-hTLR1 or anti-hTLR2 antibody, but not the anti-hTLR6 antibody. By binding to both TLR1 and TLR2, CU-T12-9 facilitates TLR1/2 heterodimer formation, activating downstream signaling. Fluorescence anisotropy assays revealed competitive binding to the TLR1/2 complex between CU-T12-9 and Pam3CSK4, with an IC50 of 54.4 nM. CU-T12-9 signals through nuclear factor κB (NF-κB) and elevates downstream effectors tumor necrosis factor-α (TNF-α), interleukin-10 (IL-10), and inducible nitric oxide synthase (iNOS)[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 250 mg/mL (690.02 mM), Sonication is recommended.
|
| Keywords | obesity | inflammatory | carcinoma | cancer | Toll-like Receptor (TLR) | TLR1/2 | diseases | specific | infectious | bladder | CU-T-12-9 | CUT129 | CU-T12-9 | Inhibitor | breast | asthma | CU T12 9 | inhibit | influenza | pancreatic |
| Inhibitors Related | Polyinosinic-polycytidylic acid sodium | CU-CPD107 | Imiquimod hydrochloride | Hydroxychloroquine | Chloroquine phosphate | Hydroxychloroquine sulfate | Chloranil | Chloroquine | CU-115 | Imiquimod | TLR3-IN-1 | Resiquimod |
| Related Compound Libraries | 細(xì)胞重編程化合物庫(kù) | 經(jīng)典已知活性庫(kù) | 膜蛋白靶向化合物庫(kù) | 細(xì)胞焦亡化合物庫(kù) | NO PAINS 化合物庫(kù) | 腫瘤免疫治療小分子化合物庫(kù) | 已知活性化合物庫(kù) |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:2471982-20-2
$53.00 / 1mg
-
CAS:2162962-69-6
$44.00 / 1mg
-
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$55.00/1box |
VIP1Y
|
hebei hongtan Biotechnology Co., Ltd
|
2024-03-14 |
|
|
$10.00/1mG |
VIP1Y
|
CONTIDE BIOTECH CO.,LTD
|
2024-05-14 |
|
|
$1.00/1box |
VIP6Y
|
Shanghai Longyu Biotechnology Co., Ltd.
|
2024-11-23 |
United States